P

Prime Medicine Inc
NASDAQ:PRME

Watchlist Manager
Prime Medicine Inc
NASDAQ:PRME
Watchlist
Price: 2.9 USD 3.94% Market Closed
Market Cap: 380.4m USD
Have any thoughts about
Prime Medicine Inc?
Write Note

P/E
Price to Earnings

-1.7
Current
-4.3
Median
22.1
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-1.7
=
Market Cap
380.4m USD
/
Net Income
-219.2m USD
All Countries
Close
Market Cap P/E
US
Prime Medicine Inc
NASDAQ:PRME
380.4m USD -1.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -180 796.7
US
Abbvie Inc
NYSE:ABBV
310.3B USD 61.1
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 33.5
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 915.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD -213.4
US
Epizyme Inc
F:EPE
94.1B EUR -472.6
AU
CSL Ltd
ASX:CSL
133.7B AUD 31.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 16.6
US
Seagen Inc
F:SGT
39.3B EUR -54.7
NL
argenx SE
XBRU:ARGX
36.2B EUR -136.1
Earnings Growth P/E to Growth
US
P
Prime Medicine Inc
NASDAQ:PRME
Average P/E: 211.6
Negative Multiple: -1.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 796.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.6 N/A N/A
AU
CSL Ltd
ASX:CSL
31.6
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -136.1 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-1.7
2-Years Forward
P/E
-2.1
3-Years Forward
P/E
-2.1

See Also

Discover More